Cargando…

Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection

Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Yi-Ling, Morihara, Daisuke, Shibata, Kumiko, Yamauchi, Ryo, Fukuda, Hiromi, Kunimoto, Hideo, Takata, Kazuhide, Tanaka, Takashi, Inomata, Shinjiro, Yokoyama, Keiji, Takeyama, Yasuaki, Shakado, Satoshi, Sakisaka, Shotaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266757/
https://www.ncbi.nlm.nih.gov/pubmed/30400133
http://dx.doi.org/10.3390/nu10111620
_version_ 1783375912067137536
author Ko, Yi-Ling
Morihara, Daisuke
Shibata, Kumiko
Yamauchi, Ryo
Fukuda, Hiromi
Kunimoto, Hideo
Takata, Kazuhide
Tanaka, Takashi
Inomata, Shinjiro
Yokoyama, Keiji
Takeyama, Yasuaki
Shakado, Satoshi
Sakisaka, Shotaro
author_facet Ko, Yi-Ling
Morihara, Daisuke
Shibata, Kumiko
Yamauchi, Ryo
Fukuda, Hiromi
Kunimoto, Hideo
Takata, Kazuhide
Tanaka, Takashi
Inomata, Shinjiro
Yokoyama, Keiji
Takeyama, Yasuaki
Shakado, Satoshi
Sakisaka, Shotaro
author_sort Ko, Yi-Ling
collection PubMed
description Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients were enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation were collected. Baseline Zn < 65 µg/dL (odds ratio (OR) = 10.56, p < 0.001) and baseline uric acid (UA) > 5.5 mg/dL (OR = 9.99, p = 0.001) were independent risk factors for Zn-2y deficiency. A decision-tree algorithm classified low-baseline Zn and high-baseline UA as the first two variables, suggesting that baseline hypozincemia and hyperuricemia are prognosticators for long-term zinc deficiency. Baseline Zn was negatively correlated with the Fibrosis-4 (FIB-4) index, while baseline UA was significantly higher in habitual alcohol drinkers. In conclusion, serum zinc levels should be closely monitored, considering that zinc status improvement is related to liver fibrosis regression. Hyperuricemia indicates risks of developing metabolic disorders and subsequent zinc deficiency, for which an adjustment of personal lifestyle or dietary habits should be recommended clinically.
format Online
Article
Text
id pubmed-6266757
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-62667572018-12-06 Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection Ko, Yi-Ling Morihara, Daisuke Shibata, Kumiko Yamauchi, Ryo Fukuda, Hiromi Kunimoto, Hideo Takata, Kazuhide Tanaka, Takashi Inomata, Shinjiro Yokoyama, Keiji Takeyama, Yasuaki Shakado, Satoshi Sakisaka, Shotaro Nutrients Article Zinc deficiency is frequently observed in chronic liver diseases. However, no studies have focused on the zinc status in chronic hepatitis C (HCV)-infected patients receiving direct-acting antiviral agents (DAAs). In this retrospective study, we assessed the serum zinc status in DAA-treated HCV patients with sustained virologic response for over two years (Zn-2y). Ninety-five patients were enrolled, whose baseline characteristics and blood parameters at DAA therapy initiation were collected. Baseline Zn < 65 µg/dL (odds ratio (OR) = 10.56, p < 0.001) and baseline uric acid (UA) > 5.5 mg/dL (OR = 9.99, p = 0.001) were independent risk factors for Zn-2y deficiency. A decision-tree algorithm classified low-baseline Zn and high-baseline UA as the first two variables, suggesting that baseline hypozincemia and hyperuricemia are prognosticators for long-term zinc deficiency. Baseline Zn was negatively correlated with the Fibrosis-4 (FIB-4) index, while baseline UA was significantly higher in habitual alcohol drinkers. In conclusion, serum zinc levels should be closely monitored, considering that zinc status improvement is related to liver fibrosis regression. Hyperuricemia indicates risks of developing metabolic disorders and subsequent zinc deficiency, for which an adjustment of personal lifestyle or dietary habits should be recommended clinically. MDPI 2018-11-02 /pmc/articles/PMC6266757/ /pubmed/30400133 http://dx.doi.org/10.3390/nu10111620 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ko, Yi-Ling
Morihara, Daisuke
Shibata, Kumiko
Yamauchi, Ryo
Fukuda, Hiromi
Kunimoto, Hideo
Takata, Kazuhide
Tanaka, Takashi
Inomata, Shinjiro
Yokoyama, Keiji
Takeyama, Yasuaki
Shakado, Satoshi
Sakisaka, Shotaro
Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title_full Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title_fullStr Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title_full_unstemmed Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title_short Factors Attenuating Zinc Deficiency Improvement in Direct-Acting Antiviral Agent-Treated Chronic Hepatitis C Virus Infection
title_sort factors attenuating zinc deficiency improvement in direct-acting antiviral agent-treated chronic hepatitis c virus infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6266757/
https://www.ncbi.nlm.nih.gov/pubmed/30400133
http://dx.doi.org/10.3390/nu10111620
work_keys_str_mv AT koyiling factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT moriharadaisuke factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT shibatakumiko factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT yamauchiryo factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT fukudahiromi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT kunimotohideo factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT takatakazuhide factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT tanakatakashi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT inomatashinjiro factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT yokoyamakeiji factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT takeyamayasuaki factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT shakadosatoshi factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection
AT sakisakashotaro factorsattenuatingzincdeficiencyimprovementindirectactingantiviralagenttreatedchronichepatitiscvirusinfection